Simultaneous Chromosome 7 and 17 Gain and Sex Chromosome Loss Provide Evidence that Renal Metanephric Adenoma is Related to Papillary Renal Cell Carcinoma

The renal adenomas can be confused by imaging diagnosis with malignant renal tumors, but there are also real biological dilemmas to determine their behavior. The consensus decisions are the following. (1) The adenoma of clear cells is not accepted, instead it is considered that all the clear-cell tumors are carcinomas, with greater or lesser aggressiveness. (2) Among the papillary neoplasms the WHO 2004 renal cell tumors classification are considered as papillary adenomas tumors with a maximum diameter of 5 mm and may represent a continuum biological process to papillary renal cell carcinoma. The papillary adenomas associated with End-kidney and/or acquired cystic disease may have a different pathogenesis. (3) To consider a tumor as an oncocytoma the size is not important, only the cytological features, microscopic, ultrastructural, and immunohistochemically can help, but some chromosomal observations introduce some questions about its relation with the chromophobe renal cell carcinoma. (4) Finally, the metanephric adenoma, a tumor with some morphological similarity with the nephroblastoma must be considered in the renal adenomas diagnosis.

Download Full-text

Renal Metanephric Adenoma Mimicking Papillary Renal Cell Carcinoma on Computed Tomography: A Case Report

Urologia Internationalis ◽

10.1159/000341940 ◽

2013 ◽

Vol 90 (3) ◽

pp. 369-372 ◽

Cited By ~ 5

Author(s):

Akinori Masuda ◽

Takao Kamai ◽

Tomoya Mizuno ◽

Tsunehito Kambara ◽

Hideyuki Abe ◽

...

Keyword(s):

Computed Tomography ◽

Renal Cell Carcinoma ◽

Case Report ◽

Cell Carcinoma ◽

Renal Cell ◽

Papillary Renal Cell Carcinoma ◽

Metanephric Adenoma

Download Full-text

Adult Nephroblastoma with Predominant Epithelial Component: A Differential Diagnostic Candidate of Papillary Renal Cell Carcinoma and Metanephric Adenoma—Report of Three Cases

Case Reports in Pathology ◽

10.1155/2013/675875 ◽

2013 ◽

Vol 2013 ◽

pp. 1-5

Author(s):

Shiho Watanabe ◽

Hiroshi Naganuma ◽

Michio Shimizu ◽

Satoshi Ota ◽

Shin-ichi Murata ◽

...

Keyword(s):

Renal Cell Carcinoma ◽

Cell Carcinoma ◽

Tumor Cells ◽

Renal Cell ◽

Benign Tumor ◽

Renal Tumor ◽

Papillary Renal Cell Carcinoma ◽

Metanephric Adenoma ◽

Old Females ◽

Epithelial Element

Although nephroblastoma is the commonest renal tumor of childhood, it is rare in adults. In cases of predominantly epithelial type occurring in adulthood, it might be difficult to distinguish it from papillary renal cell carcinoma and metanephric adenoma. Here, we report three cases of adult epithelial nephroblastoma in 24-, 76-, and 21-year-old females. Histologically, the tumors were composed of papillotubular architectures of small and uniform tumor cells with high nucleocytoplasmic ratio without blastemal element. Immunohistochemically, the tumor cells were positive for WT-1 and CD57 but negative for AMACR, which was helpful to exclude the possibility of papillary renal cell carcinoma. Metanephric adenoma is a benign tumor, which can be distinguished by the observation of the cellular atypism and growth pattern. However, nephroblastoma with predominant epithelial element mimics the malignant counterpart of metanephric adenoma, that is, “metanephric adenocarcinoma.”

Download Full-text

A Composite Renal Tumor: Metanephric Adenofibroma, Wilms Tumor, and Renal Cell Carcinoma: A Missing Link?

Pediatric and Developmental Pathology ◽

10.2350/11-03-1007-cr.1 ◽

2012 ◽

Vol 15 (1) ◽

pp. 65-70 ◽

Cited By ~ 10

Author(s):

Maria Laura Galluzzo ◽

Maria T. Garcia de Davila ◽

Gordan M. Vujanić

Keyword(s):

Renal Cell Carcinoma ◽

Cell Carcinoma ◽

Renal Cell ◽

Renal Tumor ◽

Wilms Tumor ◽

Papillary Renal Cell Carcinoma ◽

Renal Tumors ◽

Metanephric Adenoma ◽

Missing Link ◽

Additional Support

A coexistence of different renal tumors has rarely been reported. The most commonly described association is of Wilms tumor and renal cell carcinoma. Metanephric adenofibroma has also been associated with Wilms tumor or papillary renal cell carcinoma. Another reported association is metanephric adenoma and papillary renal cell carcinoma with sarcomatoid dedifferentiation. Herein we describe a complex renal tumor containing areas of metanephric adenofibroma, Wilms tumor, and undifferentiated renal cell carcinoma in a previously healthy 18-year-old boy. The tumor showed histologic and immunohistochemical features of these 3 different tumors, offering additional support to the view that these 3 tumors are related.

Download Full-text

Correlation of germline MET mutation with response to the dual Met/VEGFR-2 inhibitor foretinib in patients with sporadic and hereditary papillary renal cell carcinoma: Results from a multicenter phase II study (MET111644).

Journal of Clinical Oncology ◽

10.1200/jco.2012.30.5_suppl.372 ◽

2012 ◽

Vol 30 (5_suppl) ◽

pp. 372-372 ◽

Cited By ~ 5

Author(s):

Ramaprasad Srinivasan ◽

Donald P. Bottaro ◽

Toni K. Choueiri ◽

Ulka N. Vaishampayan ◽

Jonathan E. Rosenberg ◽

...

Keyword(s):

Renal Cell Carcinoma ◽

Cell Carcinoma ◽

Renal Cell ◽

Kinase Inhibitor ◽

Safety Data ◽

Papillary Renal Cell Carcinoma ◽

Chromosome 7 ◽

Tissue Samples ◽

Mutational Status ◽

Pathway Activation

372 Background: Activating mutations and/or amplifications in MET have been described in patients (pts) with papillary renal cell carcinoma (PRC). Foretinib, an oral multi-kinase inhibitor targeting MET, VEGF, RON, AXL, and TIE-2 receptors, was evaluated in a phase 2 study in pts with PRC. An important objective of this study was to evaluate whether activation of the MET receptor pathway by mutation, amplification, or gain of chromosome 7 was predictive for or correlated with clinical outcomes. Methods: Pts were stratified based on status of MET pathway activation. Blood samples were collected at screening for determination of germline MET mutational status. Archival tumor tissue samples were obtained for the analysis of somatic MET mutation, amplification of the MET locus (7q31), and gain of chromosome 7 using standardized assays. Results: A total of 74 pts were enrolled on the trial (37 each in intermittent and daily dosing arms); overall efficacy and safety data are reported separately at this meeting. Sixty-seven pts were evaluable for both mutation status and response. 5/10 pts (50%) with a germline MET mutation experienced a PR, while 5 pts (50%) had SD as their best response, including 4 pts who demonstrated tumor SLD reductions of > 10%, but did not achieve PR by RECIST 1.0. Responses were also seen in pts without germline MET mutation. However, the presence of a germline MET mutation was highly predictive of a response as only 5/57 pts (9%) without a mutation experienced a PR. Other measures of MET pathway activation did not appear to correlate with activity with only 1/5 pts (20%) with somatic MET mutation having a PR; furthermore, in the absence of a concomitant MET mutation, no responses were seen in patients with MET amplification (n=2) and only 1/18 (5%) pts with a gain of chromosome 7 experienced a PR. Conclusions: The presence of germline MET mutations correlated strongly with activity of the MET inhibitor foretinib in pts with PRC. These data provide early proof of principle that MET may be a valid therapeutic target in a subset of patients with PRC.

Download Full-text

Metanephric adenoma with BRAF V600K mutation and a doubtful radiological imaging: pitfalls in the diagnostic process

Medical Molecular Morphology ◽

10.1007/s00795-020-00269-z ◽

2020 ◽

Author(s):

Niccolo Lenci ◽

Pierconti Francesco ◽

Eros Scarciglia ◽

Vincenzo Fiorentino ◽

Mattia Schino ◽

...

Keyword(s):

Renal Cell Carcinoma ◽

Cell Carcinoma ◽

Renal Cell ◽

Mutational Analysis ◽

Wilms Tumor ◽

Immunohistochemical Analysis ◽

Papillary Renal Cell Carcinoma ◽

Diagnostic Process ◽

Radiological Imaging ◽

Metanephric Adenoma

Abstract Metanephric adenoma (MA) is an uncommon benign renal tumor whose histomorphological aspect resembles that of Wilms’ tumor and papillary renal cell carcinoma. From a diagnostic and therapeutic perspective, recognition of this entity is important as it has a more favorable clinical outcome compared with Wilms’ tumor and papillary renal cell carcinoma. MA should not be treated with nephrectomy if the tumor size is small, opting for a conservative treatment. However, the preoperative diagnosis of this disease is extremely challenging. The present study describes a case of this rare disease, showing an ambiguous radiological imaging and that only after a percutaneous biopsy, was defined as a MA and treated with partial nephrectomy. Moreover, the histological diagnosis of this case was partially complicated by the equivocal immunohistochemical analysis showing negativity for BRAF VE1 staining. Only the mutational analysis demonstrated the presence of the BRAF V600K mutation (for the first time described in a case of metanephric adenoma), highlighting the necessity of sequencing in case of MA with negativity for BRAF VE1 clone.

Download Full-text